Most Recent Articles by James G. DIckinson
Medtronic, as part of the settlement, will pay $602,000 to a whistleblower to settle charges it caused physicians to submit false claims to federal health programs.
President Barack Obama's recently unveiled Precision Medicine Initiative hopes to develop a new model of patient-driven research with the promise of accelerating biomedical discoveries and provide clinicians with new tools, knowledge, and therapies.
FDA posted a revised draft guidance document on its brief summary and adequate directions for use concerning risk information in DTC print ads to reflect "recent social science research."
With POC on the march, the FDA will have to stretch its monitoring efforts to keep up
Public Citizen tells FDA it should withdraw draft guidance that it believes will allow drugmakers to tell physicians marketed drugs are less risky than their labels indicate.
More Articles by James G. DIckinson
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- US pharma market value projected to be $550 billion in five years
- Biosimilar uptake will require companies to tell a trustworthy backstory
- Lawmakers propose allowing pharma companies to share some off-label information
- Apple's ResearchKit: Five Guidelines for Pharma
- Everyday Health buys rare-disease agency Cambridge BioMarketing
- Five things for pharma marketers to know: Thursday, March 26
- Rare Diseases: Target Practice
- Physicians call for emphasis on women's health research and care
- Implement a Direct-to-Patient Approach to Increase Patient Engagement and Retention
- Bristol-Myers Squibb licenses autoimmune program from Novo Nordisk